Devex interview about digital adherence technologies: “We hope that our research will contribute to the WHO policy”

Over the years, digital technologies have been introduced to improve patients’ adherence to tuberculosis (TB) treatment, but with little research showing how feasible these technologies are. Therefore, the ASCENT project launched a global study on digital adherence technologies. Devex interviewed Kristian van Kalmthout, digital health consultant at KNCV Tuberculosis Foundation and project director at ASCENT, about the launch of the research phase

Experts started to enroll drug-sensitive patients across Ethiopia, the Philippines, South Africa, Tanzania, and Ukraine with high TB burdens or high multidrug/rifampicin-resistance into the study. “We hope that our research and our evaluations will contribute to the World Health Organization policy improvements to [TB] treatment,” Kristian van Kalmthout told Devex.

The Unitaid funded and supported ASCENT project is led by KNCV Tuberculosis Foundation in partnership with The Aurum InstituteLondon School of Hygiene & Tropical Medicine, and PATH.

Read the Devex article about the ASCENT project here.

KNCV has been fighting TB since its establishment in 1903. Over the past 117 years, the organization has acquired indispensable knowledge and experience in the field of effective TB control, resulting in pre-elimination in the Netherlands and significant contributions to global evidence generation, policy development and TB program implementation worldwide.

Our experts
KNCV governance framework
Our patroness
Partner with us

Tuberculosis is still one of the major causes of preventable death in the world and claims over 4000 lives a day, leading to over 1,5 million deaths a year.

Patient stories

The story of Abdurahim
The story of Fikeraddis
The story of Issayas
The story of Zarina
The story of Maxine
The story of Saanvi

Sorry

De versie van de browser die je gebruikt is verouderd en wordt niet ondersteund.
Upgrade je browser om de website optimaal te gebruiken.